Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Avapro AGs Hit Market, Talion AG Won’t Arrive Until March
December 8, 2017
- FDA Clears Sunovion’s Nebulized COPD Drug
December 7, 2017
- Lenvima Filed for HCC in Taiwan: Eisai
December 7, 2017
- Astellas, Univ. of Tokyo, Chiba Univ. Strike Collaborative Research Deal on Rice-Based Oral Vaccine
December 7, 2017
- Positive Update Out for Burosumab in Adult XLH: Kyowa Kirin
December 6, 2017
- GSK Poised to Re-Enter Japan Oncology Space with Novel Myeloma Drug
December 6, 2017
- Astellas Snapping Up US Mitochondrial Disease Specialist Mitobridge
December 5, 2017
- Takeda Officially Organizes “Shonan Health Innovation Park”; Ex-Lilly Japan R&D Chief to Wield the Baton
December 5, 2017
- Daiichi Sankyo Winds Up Deal on Thrombus Dissolving Agent amid Re-Prioritization Drive
December 5, 2017
- ASKA Expands Testosterone Deal with TesoRx Pharma
December 5, 2017
- Pfizer Sues Meiji Seika Pharma, Claiming Infringement of Zyvox Patent
December 5, 2017
- Takeda Spin-Off Chordia Aims to Develop Oncology Blockbuster Drug
December 4, 2017
- Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
- Hiroshima Univ. Spinoff Initiates PIII Study for Regenerative Cellular Medicine for Chondrogenesis in Knee
December 1, 2017
- Novartis to Keep Close Eye on Discussions on Clozaril at Chuikyo, Expects Strengthened Measures to Promote Proper Use
November 30, 2017
- Pfizer Lifts Shipment Adjustments of 3 Brands/4 Products after Resuming Operations at Hurricane-Hit Plant in Puerto Rico
November 30, 2017
- Takeda Launches PI Study of Zika Vaccine Candidate
November 30, 2017
- Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
- MSD, Astellas to Copromote Januvia-Suglat Combo
November 29, 2017
- Nichi-Iko Rolls Out Remicade Biosimilar
November 29, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…